PLA–Inhibitor (stoPLA) – New class of NSAIDs for oral and transdermal inflammation treatment
PLA2 enzymes exist as secreted forms and cytosolic forms. The cytosolic or cPLA2 enzymes appear to play a key role in the pathway leading to the formation of platelet activating factor and eicosanoids. PLA2 enzymes cleave phospholipids at the sn-2-position. This metabolic step isinstrumental in a variety of pathogenic processes causingpain and inflammation.
Presently glucocorticoids are used for inhibition of PLA2. Unfortunately, glucocorticoids have serious side effectswhich limit their use as medication for inflammationtreatment.
Further Information: PDF
Phone: +49 (0)208/94105 10
Dipl.-Ing. Alfred Schillert
Alle Nachrichten aus der Kategorie: Technology Offerings
Climate change drives plants to extinction in the Black Forest in Germany
Climate change is leaving its mark on the bog complexes of the German Black Forest. Due to rising temperatures and longer dry periods, two plant species have already gone extinct…